Ristova 100mg Injection – 1 Vial x 10ml

Targeted Treatment for Blood Cancers and Autoimmune Disorders

Ristova 100 mg Injection is a powerful monoclonal antibody therapy designed to selectively target CD20-positive B-cells—cells that play a central role in the development of many blood cancers and autoimmune diseases. As the first therapeutic monoclonal antibody developed to act on CD20 markers, Ristova represents a major advancement in modern immunotherapy.

By precisely identifying and attacking abnormal B-cells, Ristova helps control disease progression while supporting the body’s natural immune response.

How Ristova Works

Ristova targets cells that express the CD20 marker on their surface. These B-cells are involved in conditions such as lymphoma, leukemia, and certain autoimmune disorders. Once bound to CD20, Ristova works through two complementary mechanisms: it directly damages the targeted cells and activates the body’s immune system to eliminate them.

This dual action enhances treatment effectiveness while allowing for selective targeting, minimizing effects on non-CD20 cells.

Broad Oncology Applications

Ristova is approved for the treatment of a wide range of blood cancers in adults, including follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. It is effective in newly diagnosed cases as well as relapsed or refractory disease, providing flexibility across different stages of cancer management.

In pediatric patients aged six months and older, Ristova is approved for advanced-stage CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia. This makes it an important therapeutic option across age groups.

Autoimmune Disease Management

Beyond oncology, Ristova is also used in the treatment of autoimmune conditions where B-cells contribute to immune system dysfunction. It is approved for adult patients with rheumatoid arthritis and pemphigus vulgaris, and for both adults and children aged two years and older with granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis.

By reducing abnormal B-cell activity, Ristova helps control inflammation and disease progression in these conditions.

Flexible Use in Combination Therapy

Ristova 100 mg Injection may be administered alone or in combination with other medicines, depending on the condition being treated. This adaptability allows healthcare providers to tailor treatment plans based on disease severity, patient response, and clinical guidelines.

Administration and Medical Supervision

Ristova is administered as an injection under strict medical supervision, typically in specialized healthcare settings. Dosage and treatment schedules are determined by the treating physician based on the patient’s diagnosis, age, and clinical condition.

Call to Action

Ristova 100 mg Injection offers a scientifically advanced, targeted approach to treating CD20-positive blood cancers and autoimmune diseases. If you or a loved one requires specialized immunotherapy, consult a qualified healthcare professional to determine whether Ristova is the right treatment option. Trust modern monoclonal antibody therapy to deliver precise, effective, and evidence-based care.